XML 35 R22.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Accrued Expenses and Other Current Liabilities | 12 Months Ended
--- | ---
Dec. 31, 2024
Payables and Accruals [Abstract] |
Accrued Expenses and Other Current Liabilities | ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other current liabilities consisted of the following:
| December 31,
(in thousands) | 2024 |  | 2023
Accrued payments due to AstraZeneca | $ | 12,077 |  |  | $ | 3,680 |
Accrued gross to net revenue liabilities | 10,112 |  |  | 3,258 |
Accrued sales and marketing expenses | 3,696 |  |  | 3,223 |
Other | 8,757 |  |  | 4,880 |
Total accrued expenses and other current liabilities | $ | 34,642 |  |  | $ | 15,041 |

X
- Definition The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1 + Details
Name: | us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_PayablesAndAccrualsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration